StockVS

Phreesia, Inc. (PHR) Aktienanalyse

Gesundheitswesen

Phreesia, Inc.

$8.95

+$0.03 (+0.34%)

Zuletzt aktualisiert: 26. Mai 2026

Kursverlauf

Aktuelle Nachrichten

Nachrichten von Drittquellen bereitgestellt. Keine Finanzberatung.

Analyse

Unternehmensübersicht

Phreesia, Inc. operates as an integrated software and payment platform provider within the healthcare sector, specifically targeting the Health Information Services industry in the United States and Canada. This positioning allows the company to deliver essential digital infrastructure for appointment scheduling, patient reminders, and referral management, effectively automating critical administrative workflows for healthcare providers. The enterprise currently commands a market capitalization of $661.95M, supported by a robust workforce of 2082 employees and trailing twelve-month revenue of $463.20M. These valuation and revenue figures indicate that Phreesia has established itself as a significant player capable of generating substantial top-line growth, yet the negative net income suggests the business is still in an investment phase where capital expenditure and operating expenses exceed current profitability levels.

Finanzielle Gesundheit

The company reported revenue of $463.20M over the trailing twelve months, while recording a net income loss of $-5,379,000 and an EBITDA of $14.42M. The substantial divergence between the positive EBITDA and the negative net income reveals a significant cost structure burden, primarily driven by high interest expenses or non-operating costs that erode bottom-line profitability despite healthy core earnings before interest, taxes, depreciation, and amortization. Despite the accounting loss, Phreesia generated free cash flow of $33.37M, which provides the organization with considerable financial flexibility to fund operations, invest in technology, or pursue strategic acquisitions without relying on external equity financing. The margins reflect this transitional state, with a gross margin of 68.2% indicating strong pricing power or low cost of goods sold, contrasted sharply by an operating margin of -46.7% and a profit margin of -1.2% that highlight the heavy overhead required to scale the SaaS platform. Liquidity is further supported by a cash balance of $439.85M, which vastly outweighs the total debt of $12.64M, resulting in a conservative balance sheet characterized by a low debt-to-equity ratio of 2.60. Short-term liquidity is robust, evidenced by a current ratio of 2.44, meaning the company holds more than double the current assets necessary to cover its short-term liabilities. However, the return metrics reveal challenges in capital efficiency, with a return on equity of -1.9% and a return on assets of -0.3%, indicating that management has not yet generated positive returns on the substantial capital base employed in the business.

Bewertungsanalyse

Valuation multiples present a complex picture given the lack of traditional earnings coverage, as the P/E Ratio (TTM) is listed as N/A due to the negative net income, while the forward P/E stands at 7.29. This disparity implies that the market is pricing the stock based on anticipated future earnings normalization rather than current profitability, suggesting an expectation that losses will narrow in the coming fiscal periods. Relative to its book value, the price-to-book ratio is 2.06, indicating that the market values the company at a premium of over twice its net asset value, likely reflecting the intangible value of its proprietary software and platform ecosystem. Alternative valuation metrics provide additional context, with a price-to-sales ratio of 1.43 and an EV/EBITDA of 16.27, which suggest the market is willing to pay a moderate multiple for revenue given the high growth trajectory. The stock has exhibited significant volatility over the past year, trading between a 52-week low of $10.75 and a 52-week high of $32.76, with the current price reflecting the market's ongoing assessment of its turnaround potential. The beta of 0.72 indicates that the stock is less volatile than the broader market, suggesting it may offer a lower risk profile relative to systematic market movements despite its speculative nature due to the lack of earnings.

Growth & Income

Phreesia demonstrates aggressive expansion with a revenue growth rate of 45.7% year-over-year, while earnings growth is listed as N/A due to the current lack of net income. The absence of earnings growth relative to revenue highlights a classic SaaS scaling dynamic where top-line expansion outpaces bottom-line realization, implying that the company is prioritizing market share acquisition over immediate profit generation. As the company does not pay dividends, the dividend yield is N/A and the payout ratio is 0.0%, meaning all generated cash is reinvested into business operations and growth initiatives rather than distributed to shareholders. This reinvestment strategy is typical for high-growth technology companies that utilize their cash reserves and positive free cash flow to fund R&D and sales expansion until they reach a sustainable level of profitability.

Vergleich mit Mitbewerbern

Phreesia, Inc. (PHR) ist in der Gesundheitsinformationsdienste-Branche tätig. So schneidet das Unternehmen im Vergleich zu seinen nächsten Mitbewerbern nach Marktkapitalisierung ab:

Unternehmen Ticker Marktkapitalisierung KGV
Phreesia, Inc. PHR $551.03M 223.0
Veeva Systems Inc. VEEV $25.87B 29.1
BrightSpring Health Services, Inc. BTSG $11.70B 78.3
Tempus AI, Inc. TEM $8.38B N/A

Das durchschnittliche KGV der Gesundheitsinformationsdienste-Branche beträgt 57.5x. Phreesia, Inc. wird mit einem KGV von 223.0 gehandelt.

Diese Analyse wurde von KI erstellt und dient nur zu Informationszwecken. Sie stellt keine Finanzberatung dar. Daten können verzögert oder ungenau sein. Führen Sie immer Ihre eigene Recherche durch und konsultieren Sie einen qualifizierten Finanzberater, bevor Sie Anlageentscheidungen treffen.

Über Phreesia, Inc.

Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. It offers solutions including appointment optimization and referral management using AI-enabled workflows; and AI-based smart answering solution patient communications supported by voice and messaging solutions; integrated payment solutions embedded in intake and post-visit workflows, and financing solutions that enable healthcare organizations to accelerate cash collections while offering flexible payment options to patients; and digital intake and clinical data capture, patient engagement and activation tools, and measurement and analytics solutions. It also offers PhreesiaPads, a self-service intake tablets; and Arrivals Kiosks, which are on-site kiosks. The company serves a range of healthcare organizations including ambulatory practices, health systems, and hospitals, as well as life sciences companies, government entities, patient advocacy, public interest and not-for-profit and other organizations. Phreesia, Inc. was incorporated in 2005 and is based in Wilmington, Delaware.

Die Unternehmensbeschreibung wird auf Englisch angezeigt.

Website besuchen →

Wichtige Kennzahlen

Marktkapitalisierung
$551.03M
KGV
223.00
52-Wochen-Hoch
$32.76
52-Wochen-Tief
$7.77
Durchschn. Volumen
1.92M
Beta
0.89

Daten bereitgestellt von Yahoo Finance über yfinance. Täglich aktualisiert.

Unternehmensinfo

Börse
NYSE
Land
United States
Mitarbeiter
1,789